| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $20.7M | — | -16.9% |
| SG&A Expense | $7.1M | — | +5.0% |
| Operating Income | -$27.8M | — | +12.2% |
| Net Income | -$23.6M | — | +17.2% |
| EPS (Basic) | -$0.38 | — | +33.3% |
| EPS (Diluted) | -$0.38 | — | +33.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $132.2M | +33.7% | +30.0% |
| Short-term Investments | $320.2M | -12.0% | +70.5% |
| Current Assets | $463.1M | -2.5% | +57.4% |
| Total Assets | $464.9M | -2.4% | +53.6% |
| Current Liabilities | $11.5M | -30.7% | -17.8% |
| Total Liabilities | $11.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$19.3M | — | +20.0% |
| Investing Cash Flow | $42.5M | — | +2880.1% |
| Financing Cash Flow | $10.1M | — | +4196.2% |
| -19.5% |
| Stockholders' Equity | $453.4M | -1.4% | +57.3% |